Patents by Inventor Clay Siegall
Clay Siegall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080317747Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: ApplicationFiled: May 7, 2008Publication date: December 25, 2008Applicant: Seattle Genetics, Inc.Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Sveltana Doronina, Brian E. Toki
-
Publication number: 20080213289Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: ApplicationFiled: January 18, 2008Publication date: September 4, 2008Applicant: SEATTLE GENETICS, INC.Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Svetlana Doronina, Brian E. Toki
-
Publication number: 20070258987Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: ApplicationFiled: May 28, 2004Publication date: November 8, 2007Inventors: Joseph Francisco, Grant Risdon, Alan Wahl, Clay Siegall, Peter Senter, Doronina Svetlana, Brian Toki
-
Patent number: 7090843Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: GrantFiled: November 28, 2000Date of Patent: August 15, 2006Assignee: Seattle Genetics, Inc.Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall
-
Publication number: 20050266002Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies-of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: ApplicationFiled: April 8, 2005Publication date: December 1, 2005Inventors: Clay Siegall, Alan Wahl, Joseph Francisco, Henry Fell
-
Publication number: 20050008637Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: ApplicationFiled: August 16, 2004Publication date: January 13, 2005Inventors: Clay Siegall, Alan Wahl, Joseph Francisco, Henry Fell
-
Publication number: 20040018194Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.Type: ApplicationFiled: May 28, 2003Publication date: January 29, 2004Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Sveltana Doronina, Brian E. Toki
-
Patent number: 5980896Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.Type: GrantFiled: June 14, 1993Date of Patent: November 9, 1999Assignee: Bristol-Myers Squibb CompanyInventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber, Clay Siegall, Stephen McAndrew
-
Patent number: 5736536Abstract: A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.Type: GrantFiled: February 6, 1997Date of Patent: April 7, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Clay Siegall, Dana Chace
-
Patent number: 5688781Abstract: A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.Type: GrantFiled: August 19, 1994Date of Patent: November 18, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Clay Siegall, Dana Chace
-
Patent number: 5328984Abstract: Proteins that are impermeable and foreign to the eukaryotic cells can now be delivered across cellular membranes into the cytosol of target cells by making a chimeric protein having specific attributes. A method of making such chimeric proteins is disclosed. As an example, a chimeric protein PE-Bar with dual enzymatic activity has been made. The chimeric proteins can be used for cytotoxic, diagnostic or therapeutic purposes, such as for compensating the deficiency or defect of an enzyme or a protein which may be causative of a disease or an abnormality.Type: GrantFiled: March 4, 1991Date of Patent: July 12, 1994Assignee: The United States as represented by the Department of Health & Human ServicesInventors: Ira H. Pastan, Prior Trevor, David J. Fitzgerald, Waldemar Debinski, Clay Siegall